Evidence map›Paper›PMID 42754807›Full record

ArticleMolecular imaging and biology2026

Proof-of-Concept of CAIX-Targeted α-Particle Delivery in a Patient-Derived Hypoxic Head and Neck Squamous Cell Carcinoma Model.

Sylvia T M Wenker, Gerben M Franssen, Janneke D M Molkenboer-Kuenen, Mark W Konijnenberg, Daphne Lobeek, Giulia Tamborino, Hans Peters, Sanne A M van Lith, Sandra Heskamp, Johan Bussink

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sylvia T M WenkerDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Gerben M FranssenDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Janneke D M Molkenboer-KuenenDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Mark W KonijnenbergDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Daphne LobeekDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Giulia TamborinoDepartment of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Hans PetersDepartment of Radiation Oncology: Radiotherapy & Oncoimmunology Laboratory, Radboudumc, Nijmegen, The Netherlands.
Sanne A M van LithDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands.
Sandra HeskampDepartment of Medical Imaging: Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands. sandra.heskamp@radboudumc.nl.ORCID http://orcid.org/0000-0001-7250-0846
Johan BussinkDepartment of Radiation Oncology: Radiotherapy & Oncoimmunology Laboratory, Radboudumc, Nijmegen, The Netherlands.

Funding

KWF Kankerbestrijding 12567Nederlandse Organisatie voor Wetenschappelijk Onderzoek 09150172010054
6 · The paper itself

Abstract

purposeTumor hypoxia correlates with a poor prognosis in many solid tumors, including head and neck squamous cell carcinoma (HNSCC). Carbonic anhydrase IX (CAIX) is an endogenous hypoxia-related marker and can be targeted using the humanized monoclonal antibody girentuximab (hG250). A potential new therapy to treat hypoxic tumors is CAIX-targeted α therapy (CAIX-TAT) as α-particles cause complex DNA damage independent of oxygen levels. Here, we investigate the targeting potential of CAIX-TAT in patient-derived HNSCC SCCNij153 xenografts.

methodsDOTA-hG250 was labeled with indium-111 (

results[

conclusionRadiolabeled hG250 binds to CAIX+ tumor regions in SCCNij153 tumor-bearing mice. Additional studies are required to assess the therapeutic potential and underlying mechanism-of-action of CAIX-TAT for hypoxic tumors.

Indexed as

Carbonic anhydrase IXHead and neck squamous cell carcinomaTargeted alpha therapyTargeted radionuclide therapyTumor hypoxia

Identifiers

PMID42754807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.